US-based contract research organisation WCCT Global is leveraging its expertise in ethnobridging and diabetes studies to address the rapid spread of Type 2 Diabetes Mellitus (T2DM) in China and the drug-development needs of the local pharmaceutical industry.
With China’s T2DM population becoming the largest in the world, WCCT is focusing on supporting the local industry in developing new medicines for its home market and for export to other countries globally, the company says.
WCCT Global has “extensive research experience in both ethnobridging and T2DM clinical research and is the worldwide market leader in conducting ethnic-sensitivity studies in various Asian populations”, it notes.
The company also operates out of the ethnically diverse region of Southern California. Specifically, 17% of all Asian Americans live in Southern California, making it the largest Asian population in the US, WCCT points out.
The company works with companies in the US and beyond that need regulatory, programme-management, data-management and strategic-consulting support, with an emphasis on overseeing and executing trials in special disease and paediatric populations as well as on ethnobridging studies and cardiac safety.
WCCT therapeutic expertise spans allergies, asthma, hepatitis C, ophthalmology, oncology, renal disease and vaccines.
